AD Neuroimmune Checkpoint and TREM2 Pathway Companies
📖 Wiki Page
company1640 wordssynced 2026-04-02
Alzheimer's Disease Neuroimmune Checkpoint and TREM2 Pathway Companies
Overview
This category page covers biotechnology and pharmaceutical companies developing therapies that target neuroimmune checkpoints and TREM2-related pathways in Alzheimer's disease. Unlike general neuroinflammation companies (see [Alzheimer's Disease Neuroinflammation Companies](/companies/ad-neuroinflammation-companies)), this page focuses specifically on:
TREM2/TREM1 axis modulation — agonist antibodies and small molecule activators
CD33 inhibition — the microglial inhibitory checkpoint
CD47/SIRP-alpha axis — "don't eat me" signal modulation
Other innate immune checkpoint targets — including TREM1, SIRP-alpha, and related receptors
These targets represent the emerging paradigm of innate immune checkpoint inhibition in neurodegeneration, analogous to the cancer immunotherapy approach of PD-1/PD-L1 checkpoint blockade — but for the brain's myeloid cell compartment.
Scientific Rationale
The Neuroimmune Checkpoint Concept
Microglia and infiltrating macrophages express a suite of inhibitory receptors that dampen their phagocytic and inflammatory activity. In neurodegenerative disease, these checkpoints become pathologically "locked," preventing microglia from clearing amyloid plaques and toxic protein aggregates:
...
Alzheimer's Disease Neuroimmune Checkpoint and TREM2 Pathway Companies
Overview
This category page covers biotechnology and pharmaceutical companies developing therapies that target neuroimmune checkpoints and TREM2-related pathways in Alzheimer's disease. Unlike general neuroinflammation companies (see [Alzheimer's Disease Neuroinflammation Companies](/companies/ad-neuroinflammation-companies)), this page focuses specifically on:
TREM2/TREM1 axis modulation — agonist antibodies and small molecule activators
CD33 inhibition — the microglial inhibitory checkpoint
CD47/SIRP-alpha axis — "don't eat me" signal modulation
Other innate immune checkpoint targets — including TREM1, SIRP-alpha, and related receptors
These targets represent the emerging paradigm of innate immune checkpoint inhibition in neurodegeneration, analogous to the cancer immunotherapy approach of PD-1/PD-L1 checkpoint blockade — but for the brain's myeloid cell compartment.
Scientific Rationale
The Neuroimmune Checkpoint Concept
Microglia and infiltrating macrophages express a suite of inhibitory receptors that dampen their phagocytic and inflammatory activity. In neurodegenerative disease, these checkpoints become pathologically "locked," preventing microglia from clearing amyloid plaques and toxic protein aggregates:
Genetic variants in TREM2 (loss-of-function) increase AD risk ~3-4x, establishing the receptor as a causal target[@jiang2024][@wang2023]. CD33 risk variants have also been identified, and CD47 is implicated in impaired amyloid clearance.
TREM2 Pathway Mechanism
TREM2 is a surface receptor on microglia that signals through the adaptor protein DAP12 (TYROBP). Activation triggers:
Syk kinase recruitment via DAP12 ITAM domain
PI3K/AKT pathway activation for cell survival
MAPK pathway for inflammatory modulation
Rho GTPase reorganization for phagocytosis
Metabolic reprogramming toward glycolysis
The net effect: microglia transition from homeostatic to disease-associated microglia (DAM) state, enhancing clearance of amyloid-beta, apoptotic neurons, and myelin debris[@butovsky2024][@decano2024].
Key Companies by Target
TREM2 Agonists
Alector, Inc.
Focus: TREM2 agonism and progranulin modulation (innate immuno-neurology)
Location: South San Francisco, CA | NASDAQ: ALEC
Key Programs:
AL002: TREM2 agonist with Alector Brain Carrier (ABC) platform. Phase 2 in early AD (INVOKE-1 trial) in partnership with Roche[@alec_corp][@jiang2024]
AL101: Progranulin antibody (PGRN) to increase progranulin levels. Phase 2 in AD in partnership with GSK
AL003: Anti-TREM2 antibody (earlier stage)
AL001: Progranulin upregulator (discontinued in AD)
Platform: Alector Brain Carrier (ABC) enables BBB crossing for antibodies, enzymes, and siRNA
Notes: Pioneer in immuno-neurology — first company to bring TREM2 agonists into Phase 2 for AD
Denali Therapeutics
Focus: TREM2 agonism and lysosomal function
Location: South San Francisco, CA | NASDAQ: DNLI
Key Programs:
DNL919 (ARS--3601): TREM2 agonist antibody. Phase 1 in AD. Uses Denali's Brain Transport Vehicle (BTV) platform for CNS penetration[@denali_corp]
DNL593 (RF-1507): Progranulin modulator. Phase 1 in FTD and PD
Platform: Brain Transport Vehicle (BTV) — engineered Fc engineering for enhanced brain exposure
Notes: Strong foundation in lysosomal biology; partnership with Roche/Genentech on TREM2
Vigil Neuroscience, Inc.
Focus: TREM2 agonism (highly focused)
Location: Cambridge, MA | NASDAQ: VIGL
Key Programs:
VIG-100: TREM2 activating antibody. Phase 1 in AD[@vigil_corp]
Earlier partnership with Amgen for TREM2 programs (discontinued)
Notes: Dedicated TREM2 company; completed IPO in 2022. Focused exclusively on microglia-targeting therapies
AC Immune SA
Focus: TREM2 agonist (AL002) and amyloid immunotherapy
Location: Lausanne, Switzerland | NASDAQ: ACIU
Key Programs:
AL002: TREM2 agonist. Phase 2 (TRAILBLAZER-ALZ 3) in collaboration with Genentech/Roche. 315 participants, NCT05189193[@acui_corp][@decano2024]
ACI-35: Phospho-tau vaccine (Phase 2)
Morphomer: Small molecule tau aggregation inhibitors
Platform: Morphomer and Suprabody platforms for small molecules and antibodies
Notes: Has partnership with Roche/Genentech for AL002. Cross-listed on Nasdaq and SIX Swiss Exchange
CD47/SIRP-alpha Inhibitors
TrueBinding, Inc.
Focus: CD47/SIRP-alpha axis modulation for AD
Location: South San Francisco, CA
Key Programs:
TB-404: Anti-CD47 antibody for AD
TB-403: Anti-CD47 for oncology (cross-development)
Notes: Private company with a focus on CD47 as a "don't eat me" checkpoint in neurodegeneration. Elevated CD47 on neurons may signal microglia not to clear toxic aggregates
NextCure, Inc.
Focus: Innate immune checkpoints including B7-H4, PVRIG, and related targets
Location: New Haven, CT | NASDAQ: NXTC
Key Programs:
NC41: B7-H4 targeting (early-stage)
NC318: PVRIG (PVRL2) targeting (discontinued in oncology)
Notes: Primarily oncology-focused but exploring neurodegeneration applications. Private programs may include myeloid checkpoint targets relevant to AD
ANX005: Anti-C1q monoclonal antibody. Phase 2 in Huntington's disease (COMPLETE-HD); expanding to AD[@annexon_corp]
ANX007: C1q inhibitor (intravitreal) for geographic atrophy
Mechanism: C1q initiates complement cascade that drives synaptic pruning. Blocking C1q prevents complement-mediated synapse loss in AD
Notes: Classical complement (C1q → C3) is a distinct but related checkpoint pathway. C1q tags synapses for microglial elimination; blocking this preserves synaptic density
NLRP3 Inflammasome Inhibitors
Nodthera Ltd.
Focus: NLRP3 inflammasome inhibition
Location: Cambridge, UK (Steward Biomedical subsidiary)
Key Programs:
NT-0796: Brain-penetrant oral NLRP3 small molecule inhibitor. Phase 1/2 in AD (NCT05632433)[@nodthera_corp]
NT-0868: Second-generation NLRP3 inhibitor
Mechanism: NLRP3 inflammasome assembly in microglia releases IL-1beta and IL-18, driving chronic neuroinflammation and tau phosphorylation
Notes: First-in-class oral therapy for neuroinflammation at its source. Nodthera was acquired by Steward Biomedical in 2025
TNF-alpha Inhibitors
INmune Bio, Inc.
Focus: Selective soluble TNF-alpha inhibition via dominant-negative TNF (XPro1595)
Location: Boca Raton, FL | NASDAQ: INMB
Key Programs:
XPro1595: Dominant-negative TNF inhibitor. Phase 2 in AD (NCT05318976) and Phase 2 in PD (NCT04472052)[@inmune_corp]
Mechanism: XPro1595 neutralizes only soluble trimeric TNF-alpha (preserves membrane-bound TNF). This prevents microglial activation and A1 astrocyte conversion without compromising immune surveillance
Notes: While TNF-alpha inhibition spans the neuroinflammation space, XPro1595's selective targeting of the soluble form distinguishes it from broad immunosuppressants. Listed here as it intersects with the microglial checkpoint pathway